Funding

Terremoto Biosciences

United States · Biotech

Develops highly targeted, small molecule medicines for cancer and rare diseases

Visit terremotobio.comFunding history

Funding history

1 round · 1 with disclosed amounts
AnnouncedRoundAmountInvestors
Series C$108MBeOne Medicines — Role not disclosedCormorant Asset Management — Role not disclosedDeep Track Capital — Role not disclosedNovo Holdings — Role not disclosedOrbiMed — Role not disclosedOsage University Partners (OUP) — Role not disclosedRA Capital Management — Role not disclosedThird Rock Ventures — Role not disclosed

Investors

BeOne MedicinesSeries CCormorant Asset ManagementSeries CDeep Track CapitalSeries CNovo HoldingsSeries COrbiMedSeries COsage University Partners (OUP)Series CRA Capital ManagementSeries CThird Rock VenturesSeries C

Coverage

Apr 15, 2026Terremoto Biosciences · Series C

Similar companies

Pathos AIClinical-stage drug developer using AI to select therapeutic assets and guide oncology trials.$237M · Series E
Star TherapeuticsBiotechnology company discovering and developing antibody therapies for diseases with significant unmet need.$200M · Private financing
iCUREXKagoshima medical-device company developing chitosan hydrogel materials for wound care, including the syringe-delivered Kitosla CX dressing.¥140M · Series A first close: equity and debt
Sourcesterremotobio.com ↗